Impact of Clinical Association Between Gout and Dementia: A Nationwide Population‐BasedCohort Study in Korea

Hyperuricemia might have neuroprotective or neurodegenerative effects on dementia via oxidative stress or inflammatory response regulation. Few studies have explored the association of hyperuricemia or gout with dementia. This retrospective cohort study aimed to investigate the association between gout and dementia in Korea. Altogether, 5,052 gout patients and 25,260 age‐ and sex‐matched controls were selected from the National Health Insurance Service (NHIS)–National Sample Cohort database. The incidence and risk of dementia were evaluated by reviewing the NHIS record. We also performed a subgroup analysis according to age group (age <65 or ≥65 years) using the standard age of 65 years for elderly and nonelderly groups and sex. During follow‐up, 81 and 558 participants in the gout and control cohorts developed dementia, respectively. The mean follow‐up duration was 4.38 years in gout patients and 4.94 years in controls. Gout patients had a hazard ratio (HR) of 0.79 for overall dementia (95% confidence interval [95% CI] 0.62–1.00) and significantly lower Alzheimer's disease risk (HR 0.73 [95% CI 0.54–0.98]) after adjusting for age, sex, household income, and comorbidities. In subgroup analysis stratified by age and sex, the inverse association between gout and the risk of overall dementia (HR 0.71 [95% CI 0.52–0.97]) and Alzheimer's disease (HR 0.67 [95% CI 0.46–0.97]) were observed in the elderly male group. On the other hand, age‐ and sex‐adjusted analysis showed that the HR for vascular dementia of gout patients was 2.31 (95% CI 1.02–5.25) in the nonelderly male group. Gout decreased the risk of incident Alzheimer's disease–type dementia, especially in elderly patients. The association between gout and dementia risk may differ according to age and disease duration.